A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity

BACKGROUND: Maraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. While MVC-resistant viruses have been identified in patients, it still remains incompletely known how they adjust their CD4 and CCR5 binding properties to resist MVC inhibition while preserving their replicativ...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Retrovirology
Main Authors: Garcia-Perez, Javier, Staropoli, Isabelle, Azoulay, Stéphane, Heinrich, Jean-Thomas, Cascajero, Almudena, Colin, Philippe, Lortat-Jacob, Hugues, Arenzana-Seisdedos, Fernando, Alcami, Jose, Kellenberger, Esther, Lagane, Bernard
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2015
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4470041/
https://ncbi.nlm.nih.gov/pubmed/26081316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12977-015-0177-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares